Fabio Parisi

List of Publications by Year
in descending order

25 papers	2,325 citations	471509 17 h-index	580821 25 g-index
26 all docs	26 docs citations	26 times ranked	4905 citing authors

#	ARTICLE	IF	CITATIONS
1	PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes. Molecular Cell, 2012, 45, 344-356.	9.7	741
2	PLX4032, a selective BRAF V600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF WT melanoma cells. Pigment Cell and Melanoma Research, 2010, 23, 190-200.	3.3	315
3	Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E149-58.	7.1	254
4	Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies. Cancer Cell, 2015, 27, 354-369.	16.8	177
5	TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Research, 2013, 41, e165-e165.	14.5	113
6	Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. Journal of the National Cancer Institute, 2012, 104, 1815-1824.	6.3	103
7	Ranking and combining multiple predictors without labeled data. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1253-1258.	7.1	74
8	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clinical Cancer Research, 2015, 21, 2138-2147.	7.0	71
9	Picking ChIP-seq peak detectors for analyzing chromatin modification experiments. Nucleic Acids Research, 2012, 40, e70-e70.	14.5	64
10	The Mammalian Sin3 Proteins Are Required for Muscle Development and Sarcomere Specification. Molecular and Cellular Biology, 2010, 30, 5686-5697.	2.3	59
11	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation, 2015, 95, 334-341.	3.7	52
12	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation, 2014, 94, 467-474.	3.7	48
13	Interactions with RNA direct the Polycomb group protein SCML2 to chromatin where it represses target genes. ELife, 2014, 3, e02637.	6.0	46
14	Oct-1 Regulates IL-17 Expression by Directing Interchromosomal Associations in Conjunction with CTCF in T Cells. Molecular Cell, 2014, 54, 56-66.	9.7	44
15	Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic. Infection Control and Hospital Epidemiology, 2020, 41, 1443-1445.	1.8	34
16	Identifying synergistic regulation involving c-Myc and sp1 in human tissues. Nucleic Acids Research, 2007, 35, 1098-1107.	14.5	33
17	Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics, 2011, 12, 230.	2.8	27
18	Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research, 2010, 12, R66.	5.0	15

#	Article	IF	Citations
19	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology, 2013, 13, 3.	1.8	15
20	Integrated analysis of tumor samples sheds light on tumor heterogeneity. Yale Journal of Biology and Medicine, 2012, 85, 347-61.	0.2	14
21	Relationship between estrogen receptor α location and gene induction reveals the importance of downstream sites and cofactors. BMC Genomics, 2009, 10, 381.	2.8	8
22	Arpeggio: harmonic compression of ChIP-seq data reveals protein-chromatin interaction signatures. Nucleic Acids Research, 2013, 41, e161-e161.	14.5	7
23	MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. BioMed Research International, 2015, 2015, 1-7.	1.9	6
24	NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget, 2014, 5, 5209-5217.	1.8	3
25	VDA, a Method of Choosing a Better Algorithm with Fewer Validations. PLoS ONE, 2011, 6, e26074.	2.5	2